CStone Pharmaceuticals
CStone Pharmaceuticals (2616.HK) Stock Competitors & Peer Comparison
See (2616.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2616.HK | HK$6.82 | -5.54% | 9.8B | -84.25 | -HK$0.08 | N/A |
| 1801.HK | HK$92.90 | -5.20% | 159B | -1328.57 | -HK$0.07 | N/A |
| 9926.HK | HK$152.10 | -1.62% | 140.1B | -236.82 | -HK$0.66 | N/A |
| 1177.HK | HK$7.25 | -3.59% | 130.9B | 61.00 | HK$0.12 | +0.96% |
| 2269.HK | HK$31.22 | -3.04% | 127.6B | 36.88 | HK$0.85 | N/A |
| 1530.HK | HK$30.48 | -5.05% | 71.3B | 32.47 | HK$0.93 | +0.83% |
| 3759.HK | HK$21.76 | -4.35% | 56.3B | 18.96 | HK$1.15 | +1.10% |
| 6821.HK | HK$103.80 | -2.72% | 40.8B | 32.91 | HK$3.09 | +1.18% |
| 1877.HK | HK$24.06 | -5.65% | 38.6B | -17.29 | -HK$1.42 | N/A |
| 9995.HK | HK$59.15 | -1.91% | 38B | -19.68 | -HK$2.98 | N/A |
Stock Comparison
2616.HK vs 1801.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1801.HK has a market cap of 159B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1801.HK trades at HK$92.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1801.HK's P/E ratio is -1328.57. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 2616.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1801.HK's competition here
2616.HK vs 9926.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 9926.HK has a market cap of 140.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 9926.HK trades at HK$152.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 9926.HK's P/E ratio is -236.82. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 9926.HK's ROE of -0.09%. Regarding short-term risk, 2616.HK is less volatile compared to 9926.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 9926.HK's competition here
2616.HK vs 1177.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1177.HK has a market cap of 130.9B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1177.HK trades at HK$7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1177.HK's P/E ratio is 61.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1177.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 1177.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1177.HK's competition here
2616.HK vs 2269.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2269.HK has a market cap of 127.6B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2269.HK trades at HK$31.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2269.HK's P/E ratio is 36.88. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2269.HK's ROE of +0.08%. Regarding short-term risk, 2616.HK is more volatile compared to 2269.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2269.HK's competition here
2616.HK vs 1530.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1530.HK has a market cap of 71.3B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1530.HK trades at HK$30.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1530.HK's P/E ratio is 32.47. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1530.HK's ROE of +0.14%. Regarding short-term risk, 2616.HK is more volatile compared to 1530.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1530.HK's competition here
2616.HK vs 3759.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 3759.HK has a market cap of 56.3B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 3759.HK trades at HK$21.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 3759.HK's P/E ratio is 18.96. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 3759.HK's ROE of +0.14%. Regarding short-term risk, 2616.HK is more volatile compared to 3759.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3759.HK's competition here
2616.HK vs 6821.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6821.HK has a market cap of 40.8B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6821.HK trades at HK$103.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6821.HK's P/E ratio is 32.91. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6821.HK's ROE of +0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 6821.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6821.HK's competition here
2616.HK vs 1877.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1877.HK has a market cap of 38.6B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1877.HK trades at HK$24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1877.HK's P/E ratio is -17.29. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1877.HK's ROE of -0.20%. Regarding short-term risk, 2616.HK is more volatile compared to 1877.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1877.HK's competition here
2616.HK vs 9995.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 9995.HK has a market cap of 38B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 9995.HK trades at HK$59.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 9995.HK's P/E ratio is -19.68. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 9995.HK's ROE of -0.58%. Regarding short-term risk, 2616.HK is more volatile compared to 9995.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9995.HK's competition here
2616.HK vs 2696.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2696.HK has a market cap of 36.4B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2696.HK trades at HK$67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2696.HK's P/E ratio is 40.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2696.HK's ROE of +0.29%. Regarding short-term risk, 2616.HK is less volatile compared to 2696.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2696.HK's competition here
2616.HK vs 1548.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1548.HK has a market cap of 35.7B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1548.HK trades at HK$17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1548.HK's P/E ratio is -25.94. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1548.HK's ROE of -0.06%. Regarding short-term risk, 2616.HK is less volatile compared to 1548.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1548.HK's competition here
2616.HK vs 9688.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 9688.HK has a market cap of 32B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 9688.HK trades at HK$29.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 9688.HK's P/E ratio is -14.74. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 9688.HK's ROE of -0.33%. Regarding short-term risk, 2616.HK is more volatile compared to 9688.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9688.HK's competition here
2616.HK vs 2096.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2096.HK has a market cap of 30.9B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2096.HK trades at HK$12.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2096.HK's P/E ratio is 39.06. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2096.HK's ROE of +0.10%. Regarding short-term risk, 2616.HK is more volatile compared to 2096.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2096.HK's competition here
2616.HK vs 6855.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6855.HK has a market cap of 26.7B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6855.HK trades at HK$73.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6855.HK's P/E ratio is -48.98. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6855.HK's ROE of -0.79%. Regarding short-term risk, 2616.HK is more volatile compared to 6855.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6855.HK's competition here
2616.HK vs 9969.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 9969.HK has a market cap of 26.3B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 9969.HK trades at HK$17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 9969.HK's P/E ratio is -62.79. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 9969.HK's ROE of -0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 9969.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9969.HK's competition here
2616.HK vs 1952.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1952.HK has a market cap of 20.2B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1952.HK trades at HK$67.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1952.HK's P/E ratio is -17.49. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1952.HK's ROE of -0.24%. Regarding short-term risk, 2616.HK is less volatile compared to 1952.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1952.HK's competition here
2616.HK vs 2162.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2162.HK has a market cap of 18.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2162.HK trades at HK$61.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2162.HK's P/E ratio is -28.50. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2162.HK's ROE of -0.20%. Regarding short-term risk, 2616.HK is more volatile compared to 2162.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2162.HK's competition here
2616.HK vs 2157.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2157.HK has a market cap of 14.3B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2157.HK trades at HK$8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2157.HK's P/E ratio is -30.58. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2157.HK's ROE of -0.51%. Regarding short-term risk, 2616.HK is less volatile compared to 2157.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2157.HK's competition here
2616.HK vs 6826.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6826.HK has a market cap of 12.5B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6826.HK trades at HK$28.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6826.HK's P/E ratio is 14.14. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6826.HK's ROE of +0.07%. Regarding short-term risk, 2616.HK is more volatile compared to 6826.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6826.HK's competition here
2616.HK vs 2171.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2171.HK has a market cap of 11.3B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2171.HK trades at HK$20.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2171.HK's P/E ratio is -12.47. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2171.HK's ROE of +0.00%. Regarding short-term risk, 2616.HK is less volatile compared to 2171.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2171.HK's competition here
2616.HK vs 1672.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1672.HK has a market cap of 10B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1672.HK trades at HK$10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1672.HK's P/E ratio is -31.82. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1672.HK's ROE of -0.15%. Regarding short-term risk, 2616.HK is more volatile compared to 1672.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1672.HK's competition here
2616.HK vs 0775.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 0775.HK has a market cap of 9.6B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 0775.HK trades at HK$0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 0775.HK's P/E ratio is -100.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 0775.HK's ROE of -0.03%. Regarding short-term risk, 2616.HK is more volatile compared to 0775.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 0775.HK's competition here
2616.HK vs 2315.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2315.HK has a market cap of 9.5B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2315.HK trades at HK$26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2315.HK's P/E ratio is 282.78. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2315.HK's ROE of -0.19%. Regarding short-term risk, 2616.HK is less volatile compared to 2315.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2315.HK's competition here
2616.HK vs 9966.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 9966.HK has a market cap of 9.2B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 9966.HK trades at HK$9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 9966.HK's P/E ratio is 49.63. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 9966.HK's ROE of +0.10%. Regarding short-term risk, 2616.HK is more volatile compared to 9966.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9966.HK's competition here
2616.HK vs 2142.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2142.HK has a market cap of 8.8B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2142.HK trades at HK$8.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2142.HK's P/E ratio is 300.67. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2142.HK's ROE of +0.02%. Regarding short-term risk, 2616.HK is more volatile compared to 2142.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2142.HK's competition here
2616.HK vs 1477.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1477.HK has a market cap of 7.7B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1477.HK trades at HK$9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1477.HK's P/E ratio is -21.91. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1477.HK's ROE of -0.08%. Regarding short-term risk, 2616.HK is more volatile compared to 1477.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1477.HK's competition here
2616.HK vs 2256.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2256.HK has a market cap of 6.9B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2256.HK trades at HK$10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2256.HK's P/E ratio is 254.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2256.HK's ROE of +0.01%. Regarding short-term risk, 2616.HK is more volatile compared to 2256.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2256.HK's competition here
2616.HK vs 1167.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1167.HK has a market cap of 6.2B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1167.HK trades at HK$7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1167.HK's P/E ratio is -35.86. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1167.HK's ROE of -0.17%. Regarding short-term risk, 2616.HK is less volatile compared to 1167.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1167.HK's competition here
2616.HK vs 6660.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6660.HK has a market cap of 5.5B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6660.HK trades at HK$4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6660.HK's P/E ratio is -17.96. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6660.HK's ROE of -0.08%. Regarding short-term risk, 2616.HK is more volatile compared to 6660.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6660.HK's competition here
2616.HK vs 2509.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2509.HK has a market cap of 4.7B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2509.HK trades at HK$21.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2509.HK's P/E ratio is -12.78. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2509.HK's ROE of -1.12%. Regarding short-term risk, 2616.HK is more volatile compared to 2509.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2509.HK's competition here
2616.HK vs 1541.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1541.HK has a market cap of 4.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1541.HK trades at HK$10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1541.HK's P/E ratio is -11.13. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1541.HK's ROE of -0.49%. Regarding short-term risk, 2616.HK is more volatile compared to 1541.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1541.HK's competition here
2616.HK vs 3681.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 3681.HK has a market cap of 3.7B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 3681.HK trades at HK$3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 3681.HK's P/E ratio is -16.42. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 3681.HK's ROE of -0.79%. Regarding short-term risk, 2616.HK is less volatile compared to 3681.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 3681.HK's competition here
2616.HK vs 2179.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2179.HK has a market cap of 3.6B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2179.HK trades at HK$8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2179.HK's P/E ratio is -6.14. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2179.HK's ROE of -0.82%. Regarding short-term risk, 2616.HK is less volatile compared to 2179.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2179.HK's competition here
2616.HK vs 1873.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1873.HK has a market cap of 3.3B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1873.HK trades at HK$1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1873.HK's P/E ratio is 22.86. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1873.HK's ROE of +0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 1873.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1873.HK's competition here
2616.HK vs 6996.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6996.HK has a market cap of 3.2B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6996.HK trades at HK$4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6996.HK's P/E ratio is -8.54. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6996.HK's ROE of -0.35%. Regarding short-term risk, 2616.HK is less volatile compared to 6996.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6996.HK's competition here
2616.HK vs 1521.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1521.HK has a market cap of 3.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1521.HK trades at HK$1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1521.HK's P/E ratio is 75.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1521.HK's ROE of +0.00%. Regarding short-term risk, 2616.HK is more volatile compared to 1521.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1521.HK's competition here
2616.HK vs 2487.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2487.HK has a market cap of 2.7B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2487.HK trades at HK$8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2487.HK's P/E ratio is -5.53. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2487.HK's ROE of -0.40%. Regarding short-term risk, 2616.HK is less volatile compared to 2487.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2487.HK's competition here
2616.HK vs 2181.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2181.HK has a market cap of 2.2B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2181.HK trades at HK$0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2181.HK's P/E ratio is -18.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2181.HK's ROE of -1.25%. Regarding short-term risk, 2616.HK is more volatile compared to 2181.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2181.HK's competition here
2616.HK vs 1875.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1875.HK has a market cap of 2.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1875.HK trades at HK$2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1875.HK's P/E ratio is 49.60. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1875.HK's ROE of +0.05%. Regarding short-term risk, 2616.HK is more volatile compared to 1875.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1875.HK's competition here
2616.HK vs 6978.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6978.HK has a market cap of 2.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6978.HK trades at HK$4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6978.HK's P/E ratio is -10.26. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6978.HK's ROE of -0.01%. Regarding short-term risk, 2616.HK is more volatile compared to 6978.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6978.HK's competition here
2616.HK vs 2126.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2126.HK has a market cap of 2B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2126.HK trades at HK$5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2126.HK's P/E ratio is -3.11. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2126.HK's ROE of -0.45%. Regarding short-term risk, 2616.HK is less volatile compared to 2126.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2126.HK's competition here
2616.HK vs 1244.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1244.HK has a market cap of 1.8B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1244.HK trades at HK$7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1244.HK's P/E ratio is -9.02. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1244.HK's ROE of -0.22%. Regarding short-term risk, 2616.HK is less volatile compared to 1244.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1244.HK's competition here
2616.HK vs 2511.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2511.HK has a market cap of 1.8B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2511.HK trades at HK$3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2511.HK's P/E ratio is -3.35. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2511.HK's ROE of -0.00%. Regarding short-term risk, 2616.HK is more volatile compared to 2511.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2511.HK's competition here
2616.HK vs 6622.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6622.HK has a market cap of 1.6B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6622.HK trades at HK$3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6622.HK's P/E ratio is -6.09. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6622.HK's ROE of -0.12%. Regarding short-term risk, 2616.HK is less volatile compared to 6622.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6622.HK's competition here
2616.HK vs 2137.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2137.HK has a market cap of 1.4B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2137.HK trades at HK$1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2137.HK's P/E ratio is -2.45. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2137.HK's ROE of -0.18%. Regarding short-term risk, 2616.HK is less volatile compared to 2137.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2137.HK's competition here
2616.HK vs 6998.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6998.HK has a market cap of 1.4B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6998.HK trades at HK$2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6998.HK's P/E ratio is -23.55. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6998.HK's ROE of -0.05%. Regarding short-term risk, 2616.HK is more volatile compared to 6998.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6998.HK's competition here
2616.HK vs 2496.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2496.HK has a market cap of 1.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2496.HK trades at HK$5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2496.HK's P/E ratio is -10.18. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2496.HK's ROE of -3.00%. Regarding short-term risk, 2616.HK is more volatile compared to 2496.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2496.HK's competition here
2616.HK vs 6628.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 6628.HK has a market cap of 1.1B. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 6628.HK trades at HK$3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 6628.HK's P/E ratio is -3.61. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 6628.HK's ROE of -0.35%. Regarding short-term risk, 2616.HK is less volatile compared to 6628.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 6628.HK's competition here
2616.HK vs 2185.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2185.HK has a market cap of 968.7M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2185.HK trades at HK$4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2185.HK's P/E ratio is -10.54. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2185.HK's ROE of -0.13%. Regarding short-term risk, 2616.HK is less volatile compared to 2185.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2185.HK's competition here
2616.HK vs 9939.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 9939.HK has a market cap of 924.8M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 9939.HK trades at HK$2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 9939.HK's P/E ratio is -5.46. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 9939.HK's ROE of +0.00%. Regarding short-term risk, 2616.HK is more volatile compared to 9939.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9939.HK's competition here
2616.HK vs 2257.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2257.HK has a market cap of 850.8M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2257.HK trades at HK$7.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2257.HK's P/E ratio is -1.56. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2257.HK's ROE of +71.56%. Regarding short-term risk, 2616.HK is less volatile compared to 2257.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2257.HK's competition here
2616.HK vs 0690.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 0690.HK has a market cap of 816.1M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 0690.HK trades at HK$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 0690.HK's P/E ratio is 15.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 0690.HK's ROE of +0.26%. Regarding short-term risk, 2616.HK is less volatile compared to 0690.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 0690.HK's competition here
2616.HK vs 2197.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 2197.HK has a market cap of 725M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 2197.HK trades at HK$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 2197.HK's P/E ratio is -0.68. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 2197.HK's ROE of +0.73%. Regarding short-term risk, 2616.HK is less volatile compared to 2197.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 2197.HK's competition here
2616.HK vs 1228.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 1228.HK has a market cap of 331.4M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 1228.HK trades at HK$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 1228.HK's P/E ratio is -0.68. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 1228.HK's ROE of +1.17%. Regarding short-term risk, 2616.HK is less volatile compared to 1228.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 1228.HK's competition here
2616.HK vs 8158.HK Comparison August 2025
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 9.8B. In comparison, 8158.HK has a market cap of 255.6M. Regarding current trading prices, 2616.HK is priced at HK$6.82, while 8158.HK trades at HK$0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -84.25, whereas 8158.HK's P/E ratio is 14.00. In terms of profitability, 2616.HK's ROE is -0.22%, compared to 8158.HK's ROE of +0.71%. Regarding short-term risk, 2616.HK is less volatile compared to 8158.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2616.HK.Check 8158.HK's competition here